Vyvanse (lisdexamfetamine) is a popular medication prescribed in Australia for managing Attention Deficit Hyperactivity Disorder (ADHD) and moderate to severe binge eating disorder. Among its range of available doses, the 70 mg capsule represents the highest strength offered, often prescribed when lower doses do not provide adequate symptom control. This blog post offers an insightful overview of Vyvanse 70 mg in the Australian context, including its uses, dosing considerations, recent product alerts, and supply status.
What Is Vyvanse 70 mg?
Vyvanse 70 mg capsules contain lisdexamfetamine dimesilate, a prodrug that converts into the active stimulant dextroamphetamine in the body. This medication works by increasing dopamine and norepinephrine levels in the brain, which helps improve focus, attention, and impulse control in individuals with ADHD. The 70 mg dose is typically reserved for patients who require a higher level of symptom management after titrating from lower doses.
Approved Uses in Australia
Vyvanse 70 mg is approved for:
- ADHD treatment in children aged 6 years and older, adolescents, and adults.
- Moderate to severe binge eating disorder in adults when non-pharmacological treatments have failed or are unsuitable.
Dosage and Administration
Vyvanse is taken once daily, preferably in the morning, to avoid insomnia. Treatment usually starts at a lower dose (commonly 30 mg) and is gradually increased based on clinical response and tolerability. The maximum recommended dose is 70 mg per day, making this the highest available strength for patients needing stronger symptom control.
If swallowing capsules is difficult, the contents can be mixed with water or soft food and consumed immediately.
Recent Product Alert
In April 2025, Takeda Pharmaceuticals Australia issued a product alert for Vyvanse capsules across all strengths, including 70 mg. The alert highlighted minor packaging errors such as typographical mistakes (“Each capsules contain…” instead of “Each capsule contains…”) and a misspelling of the company name. Importantly, these errors do not affect the medication’s safety, quality, or effectiveness. Patients are advised to continue treatment as prescribed and consult their healthcare provider if they have concerns.
Supply Situation
Since 2023, Australia has experienced ongoing supply shortages of Vyvanse, affecting multiple strengths. While the 70 mg capsules have been less impacted compared to mid-range doses (30 mg, 40 mg, 50 mg, 60 mg), availability can still fluctuate due to global manufacturing delays and increased demand.
Takeda is working closely with the Therapeutic Goods Administration (TGA) to manage supply and has reserved emergency stocks for urgent patient needs. Pharmacists are encouraged to prioritise dispensing to ongoing patients to maintain treatment continuity.
Cost and Access
Vyvanse is listed on the Pharmaceutical Benefits Scheme (PBS) in Australia, which helps reduce out-of-pocket costs for eligible patients. However, due to supply issues, patients may sometimes face challenges obtaining their prescribed dose promptly.
Summary
Vyvanse 70 mg is the highest dose available in Australia for treating ADHD and binge eating disorder, offering potent symptom control for patients who need it. Despite recent packaging alerts and ongoing supply constraints, Vyvanse remains a safe and effective medication when used as directed. If you are prescribed Vyvanse 70 mg, maintain regular communication with your healthcare provider and pharmacist to ensure consistent access and optimal treatment outcomes.